Valuation : Harrow, Inc.

Market Cap 1.43B 1.23B 1.16B 1.06B 1.98B 136B 1.99B 13.7B 5.34B 69.29B 5.39B 5.27B 223B P/E 2026 *
-357x
P/E 2027 * 17x
Enterprise Value 1.43B 1.23B 1.16B 1.06B 1.98B 136B 1.99B 13.7B 5.34B 69.29B 5.39B 5.27B 223B EV / Sales 2026 *
4.09x
EV / Sales 2027 * 2.69x
Free-Float
84.62%
Yield 2026 *
-
Yield 2027 * -
1 day-0.35%
1 week+2.23%
Current month+3.22%
1 month-4.34%
3 months+9.83%
6 months-2.86%
Current year-22.24%
1 week 36.25
Extreme 36.25
39.33
1 month 36.25
Extreme 36.25
43
Current year 28.54
Extreme 28.5401
54.85
1 year 28.54
Extreme 28.5401
54.85
3 years 7.6
Extreme 7.6
59.23
5 years 5.4
Extreme 5.4
59.23
10 years 1.35
Extreme 1.35
59.23
Manager TitleAgeSince
Chief Executive Officer 53 2011-12-16
President 43 2025-08-20
Compliance Officer - 2023-09-30
Director TitleAgeSince
Chairman 53 2021-08-18
Director/Board Member 57 2022-03-30
Director/Board Member 71 2024-01-25
Date Insider Type Main position Quantity % Market Cap. Importance
8/14/26 Exercice

Chief Technology Officer

33,750 0.0905%
5/18/26 Buy

Director

1,000 0.0027%
5/18/26 Buy

Director

1,000 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-0.16%+2.23%+5.25%+154.85% 1.43B
-1.33%-2.72%+53.81%+104.71% 1,034B
-1.02%+2.76%+54.08%+71.42% 671B
-1.21%+0.54%+20.59%+75.80% 460B
+0.10%-0.84%+29.02%+38.06% 353B
-1.05%+4.80%+24.79%+45.66% 309B
-1.20%+0.15%-1.64%+12.14% 255B
-1.42%+1.10%+56.08%+72.11% 240B
-0.88%+1.24%-17.02%-54.36% 207B
-0.64%+2.97%+33.01%+99.57% 188B
Average -0.90%+1.07%+25.80%+62.00% 371.82B
Weighted average by Cap. -1.04%+1.04%+36.31%+66.32%

Financials

2026 *2027 *
Net sales 351M 302M 283M 259M 484M 33.15B 487M 3.35B 1.3B 16.94B 1.32B 1.29B 54.57B 533M 458M 430M 393M 734M 50.34B 740M 5.09B 1.98B 25.73B 2B 1.96B 82.86B
Net income -3.92M -3.37M -3.17M -2.9M -5.41M -371M -5.45M -37.45M -14.58M -189M -14.72M -14.4M -610M 89.19M 76.74M 72.01M 65.89M 123M 8.43B 124M 852M 332M 4.31B 335M 328M 13.88B
Net Debt - -
Logo Harrow, Inc.
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Employees
373
Date Price Change Volume
26-09-04 US$38.10 -0.42% 51,644
26-09-03 US$38.26 -2.02% 449,776
26-09-02 US$39.05 +5.63% 470,454
26-09-01 US$36.97 +0.16% 359,717
26-08-31 US$36.91 -0.97% 390,196
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
38.26USD
Average target price
67.50USD
Spread / Average Target
+76.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HROW Stock